Table 1.
Demographics of patients with pulmonary mucormycosis
| Case number | Gender | Age (years) | Initial symptom | Underlying diseases | Interval between initial symptom and CT scan (days) | Laboratory finding
|
Treatment | Clinical outcome | ||
|---|---|---|---|---|---|---|---|---|---|---|
| WBC (µL) | ANC (µL) | CRP (mg/dL) or ESR (mm/hour) | ||||||||
| 1 | Male | 47 | Fever, tachycardia | Myelodysplastic syndrome, BMT | 0 | 11 800 | 718 | CRP, 16.28 | Lobectomy after antifungal therapy | Death |
| 2 | Male | 43 | Fever | Aplastic anemia | 5 | 320 | 90 | CRP, 23.61 | Antifungal therapy | Survive |
| 3 | Male | 22 | Fever | T-lymphoblastic leukemia | 12 | 70 | 0 | Not available | Lobectomy after antifungal therapy | Survive |
| 4 | Female | 13 | Fever | Long term use of steroid due to autoimmune hepatitis | 7 | 2690 | 38.7 | ESR, 23 | Antifungal therapy | Survive |
| 5 | Female | 73 | Pleuritic chest pain, fever | Diabetes mellitus, congestive heart failure | 30 | 19 750 | 3893 | ESR, 77 | Antifungal Therapy | Survive |
ANC, absolute neutrophil count; BMT, bone marrow transplantation; CRP, C-reactive protein; CT, computed tomography; ESR, erythrocyte sedimentation rate; WBC, white blood cell.
Galactomannan test was negative in all patients.